Actelion announces changes to its executive team upon completion of the transaction with Johnson
& Johnson


Actelion Pharmaceuticals Ltd /
Actelion announces changes to its executive team upon completion of the 
transaction with Johnson & Johnson 
. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire

ALLSCHWIL/BASEL,  SWITZERLAND -  14 June 2017 -  Actelion Ltd  (SIX: ATLN) today
announced  changes  to  its  executive  team  that  will  take  effect  upon the
settlement  of the public tender offer  by Johnson & Johnson's Swiss subsidiary,
Janssen Holding GmbH, for all publicly held shares of Actelion which is expected
to occur on 16 June 2017 (Settlement).

As  previously announced, Jane Griffiths will  assume the position as Actelion's
Global  Head and Otto Schwarz  will retire from his  position as Chief Operating
Officer  upon Settlement. Jean-Paul  Clozel, CEO, André  C. Muller, CFO, and Guy
Braunstein, Head of Global Clinical Development, will leave Actelion's executive
committee,  which will be dissolved as of Settlement, and move to Idorsia Ltd on
16 June  2017. Jane Griffiths  will be  supported in  her top  executive role at
Actelion  by a newly formed  leadership team. Nicholas Franco,  who has been the
Chief  Business Development  Officer, will  be a  member of this leadership team
going forward.


                                      ###


NOTES TO EDITORS

Actelion Ltd.
Actelion  Ltd. is a leading biopharmaceutical  company focused on the discovery,
development   and  commercialization  of  innovative  drugs  for  diseases  with
significant unmet medical needs.

Actelion  is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio  of PAH treatments covers the spectrum of disease, from WHO Functional
Class  (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although  not available  in all  countries, Actelion  has treatments approved by
health  authorities for a number of specialist diseases including Type 1 Gaucher
disease,  Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic  sclerosis,  and  mycosis  fungoides  in patients with cutaneous T-cell
lymphoma.

Founded  in late 1997, with now  over 2,600 dedicated professionals covering all
key  markets around the world including the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion  shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN). All
trademarks are legally protected.


For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com

The above information contains certain "forward-looking statements", relating to
the  company's business, which  can be identified  by the use of forward-looking
terminology  such as  "estimates", "believes",  "expects", "may",  "are expected
to",  "will",  "will  continue",  "should",  "would  be",  "seeks", "pending" or
"anticipates"  or similar expressions,  or by discussions  of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research  and development  programs and  anticipated expenditures  in connection
therewith, descriptions of new products expected to be introduced by the company
and  anticipated customer demand for such products and products in the company's
existing  portfolio. Such  statements reflect  the current  views of the company
with  respect to future  events and are  subject to certain risks, uncertainties
and  assumptions. Many  factors could  cause the  actual results, performance or
achievements  of the company to be materially different from any future results,
performances  or achievements that may be  expressed or implied by such forward-
looking  statements.  Should  one  or  more  of  these  risks  or  uncertainties
materialize,  or should  underlying assumptions  prove incorrect, actual results
may  vary  materially  from  those  described  herein  as anticipated, believed,
estimated or expected.

Medienmitteilung PDF: 
http://hugin.info/131801/R/2113269/803884.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate
Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content,
accuracy and originality of the information contained therein.
    
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire

http://www.actelion.com